Nutriband Inc. (NASDAQ:NTRB) Short Interest Down 22.1% in February

Nutriband Inc. (NASDAQ:NTRBGet Free Report) saw a large decrease in short interest in February. As of February 28th, there was short interest totalling 281,200 shares, a decrease of 22.1% from the February 13th total of 361,000 shares. Approximately 5.5% of the company’s shares are short sold. Based on an average daily volume of 204,900 shares, the short-interest ratio is currently 1.4 days.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Nutriband stock. Haven Private LLC acquired a new stake in shares of Nutriband Inc. (NASDAQ:NTRBFree Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 11,561 shares of the company’s stock, valued at approximately $54,000. Haven Private LLC owned approximately 0.10% of Nutriband as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 19.70% of the company’s stock.

Nutriband Trading Up 4.4 %

Shares of NASDAQ:NTRB traded up $0.28 on Monday, hitting $6.48. The company had a trading volume of 14,982 shares, compared to its average volume of 83,672. The firm’s 50-day simple moving average is $6.55 and its two-hundred day simple moving average is $5.68. Nutriband has a 1 year low of $2.25 and a 1 year high of $11.78. The company has a quick ratio of 4.83, a current ratio of 4.96 and a debt-to-equity ratio of 0.01. The firm has a market capitalization of $71.91 million, a price-to-earnings ratio of -9.12 and a beta of 1.12.

Wall Street Analyst Weigh In

Separately, Noble Financial started coverage on shares of Nutriband in a research report on Wednesday, January 22nd. They set an “outperform” rating and a $13.00 price target for the company.

View Our Latest Report on NTRB

About Nutriband

(Get Free Report)

Nutriband Inc develops a portfolio of transdermal pharmaceutical products. Its lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy.

Recommended Stories

Receive News & Ratings for Nutriband Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nutriband and related companies with MarketBeat.com's FREE daily email newsletter.